Acute lymphoblastic leukemia after temozolomide treatment for anaplastic astrocytoma in a child with a germline TP53 mutation.
We present a case of a 12-year-old female with a germline TP53 mutation who presented with anaplastic astrocytoma and subsequent acute lymphoblastic leukemia (ALL) 13 months after starting treatment with temozolomide (TMZ). The patient had no family history of malignancy except her grand father and his siblings. Although alkylating agents such as TMZ are known to induce secondary hematologic malignancy, only several cases of treatment-related acute leukemia have been reported after TMZ-alone chemotherapy for malignant gliomas. We demonstrate a rare case of TMZ-related ALL in a child with glioma possibly associated with a germline TP53 mutation.
Momota
Hiroyuki
H
Neurosurgery Division, National Cancer Center Hospital, Tokyo, Japan. momota-nsu@umin.ac.jp
Narita
Yoshitaka
Y
Nariata
Yoshitaka
Y
Miyakita
Yasuji
Y
Hosono
Ako
A
Makimoto
Atsushi
A
Shibui
Soichiro
S
D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects* / Q000627:therapeutic use; D001254:Astrocytoma / Q000188:drug therapy* / Q000235:genetics; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000235:genetics; D002648:Child; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005625:Frontal Lobe; D016158:Genes, p53 / Q000235:genetics*; D018095:Germ-Line Mutation; D006801:Humans; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000139:chemically induced*; D000077204:Temozolomide
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide